ZIOPHARM Oncology Inc (ZIOP) Expected to Announce Earnings of -$0.13 Per Share
Wall Street analysts expect that ZIOPHARM Oncology Inc (NASDAQ:ZIOP) will report ($0.13) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for ZIOPHARM Oncology’s earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.14). ZIOPHARM Oncology reported earnings of ($0.11) per share in the same quarter last year, which would indicate a negative year over year growth rate of 18.2%. The firm is scheduled to issue its next earnings results on Wednesday, November 8th.
On average, analysts expect that ZIOPHARM Oncology will report full-year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.56) to ($0.54). For the next fiscal year, analysts expect that the business will report earnings of ($0.59) per share, with EPS estimates ranging from ($0.65) to ($0.53). Zacks’ EPS averages are an average based on a survey of analysts that follow ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.13). The company had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. During the same period last year, the company earned ($1.01) earnings per share. ZIOPHARM Oncology’s revenue for the quarter was down 5.9% on a year-over-year basis.
ZIOP has been the topic of several research reports. HC Wainwright set a $10.00 price objective on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a report on Tuesday, August 1st. BidaskClub raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, ValuEngine raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $16.50.
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) traded down 2.54% during mid-day trading on Tuesday, reaching $4.98. 2,366,697 shares of the company’s stock were exchanged. The stock’s 50-day moving average is $6.05 and its 200-day moving average is $6.19. ZIOPHARM Oncology has a 52-week low of $4.94 and a 52-week high of $7.88. The stock’s market cap is $700.35 million.
Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of ZIOPHARM Oncology by 7.6% in the second quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock valued at $48,917,000 after acquiring an additional 553,933 shares during the period. State Street Corp boosted its position in shares of ZIOPHARM Oncology by 12.8% in the second quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock valued at $28,342,000 after acquiring an additional 517,057 shares during the period. Morgan Stanley boosted its position in shares of ZIOPHARM Oncology by 19.5% in the first quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock valued at $12,610,000 after acquiring an additional 324,774 shares during the period. Northern Trust Corp boosted its position in shares of ZIOPHARM Oncology by 10.1% in the second quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock valued at $10,144,000 after acquiring an additional 149,067 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of ZIOPHARM Oncology by 3.9% in the first quarter. Geode Capital Management LLC now owns 1,016,427 shares of the biotechnology company’s stock valued at $6,444,000 after acquiring an additional 38,173 shares during the period. 41.91% of the stock is owned by institutional investors.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.